An Open Label, Single-arm, Phase I Study of JWCAR029 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Latest Information Update: 28 Nov 2023
At a glance
- Drugs Relmacabtagene-autoleucel (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Sponsors Shanghai Ming Ju Biotechnology
Most Recent Events
- 21 Nov 2023 Status changed from not yet recruiting to withdrawn prior to enrolment as no subjects were enrolled due to the COVID-19 pandemic.
- 08 Mar 2022 New trial record